Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 10,040 Shares of Stock

by · The Cerbat Gem

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) Director Victoria Vakiener sold 10,040 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $67.68, for a total value of $679,507.20. Following the completion of the sale, the director directly owned 35,723 shares of the company’s stock, valued at $2,417,732.64. The trade was a 21.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Arrowhead Pharmaceuticals Trading Up 1.2%

NASDAQ:ARWR traded up $0.83 during midday trading on Tuesday, hitting $69.83. 1,157,383 shares of the company traded hands, compared to its average volume of 2,158,861. The firm has a market capitalization of $9.49 billion, a P/E ratio of -872.77 and a beta of 1.28. The firm’s fifty day moving average is $49.13 and its 200-day moving average is $31.68. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $72.36. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43.

Wall Street Analyst Weigh In

A number of research firms recently commented on ARWR. Morgan Stanley lifted their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 26th. The Goldman Sachs Group boosted their target price on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a research report on Thursday, November 20th. HC Wainwright increased their price target on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $61.89.

Get Our Latest Stock Report on Arrowhead Pharmaceuticals

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of ARWR. iSAM Funds UK Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at approximately $29,000. Virtus Advisers LLC bought a new position in Arrowhead Pharmaceuticals in the second quarter worth approximately $34,000. Salomon & Ludwin LLC purchased a new stake in Arrowhead Pharmaceuticals during the third quarter worth $34,000. Nisa Investment Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 75.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,308 shares in the last quarter. Finally, Federated Hermes Inc. purchased a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at $52,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.

Read More